ReviewPediatric nephrology (Berlin, Germany)2012
Hepcidin in anemia of chronic kidney disease: review for the pediatric nephrologist.
Review in Pediatric nephrology (Berlin, Germany), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Hepcidin and arterial stiffness in children with systemic lupus erythematosus and lupus nephritis: A cross-sectional study.PloS one · 2019Trial
- Pilot study of the effect of cholecalciferol supplementation on hepcidin in children with chronic kidney disease: Results of the D-fense Trial.Pediatric nephrology (Berlin, Germany) · 2017Trial
- The Growth Attainment, Hematological, Iron Status and Inflammatory Profile of Guatemalan Juvenile End-Stage Renal Disease Patients.PloS one · 2015Trial
- Renal damage-induced hepcidin accumulation contributes to anemia in angiotensinogen-deficient mice.Clinical science (London, England : 1979) · 2025Article
- Article
- Article
- Anemia in Pediatric Kidney Transplant Recipients-Etiologies and Management.Frontiers in pediatrics · 2022Review
- The Influence of Inflammation on Anemia in CKD Patients.International journal of molecular sciences · 2020Review
- Review
- Is hepcidin related with anemia and bone mineral metabolism in children with non-dialysis chronic kidney disease?Turk pediatri arsivi · 2019Article
- Protective Role of Histidine Supplementation Against Oxidative Stress Damage in the Management of Anemia of Chronic Kidney Disease.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Anemia in chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2018Review
- Hepcidin and risk of anemia in CKD: a cross-sectional and longitudinal analysis in the CKiD cohort.Pediatric nephrology (Berlin, Germany) · 2015Article
- Association of higher erythropoiesis stimulating agent dose and mortality in children on dialysis.Pediatric nephrology (Berlin, Germany) · 2014Article
- Management of anemia with erythropoietic-stimulating agents in children with chronic kidney disease.Pediatric nephrology (Berlin, Germany) · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anemia coincident with hyporesponsiveness to erythropoiesis-stimulating agents is an ongoing and prevalent problem in children with chronic kidney disease (CKD). The recently identified iron-regulatory protein hepcidin appears likely to play a significant role in this problem. Hepcidin up-regulation in the setting of CKD, with subsequent increased serum levels, results in impaired iron absorption from the intestine and decreased iron release from body storage sites. Ultimately, in the setting of such elevated levels, a state of functional iron deficiency may develop and lead to anemia due to iron-restricted erythropoiesis. Elevated hepcidin levels are expected in the face of decreased glomerular filtration rate and inflammation. Based on current evidence, it seems likely that hepcidin represents a potentially modifiable mediator of anemia of CKD and is thus a potential target for future anemia therapy. Currently, increased removal via intensified dialysis and-/or blockade of the inflammatory pathway appear to be two viable generic strategies for reducing hepcidin levels. Goals of directly manipulating the hepcidin pathway should offer the pediatric clinician new options for treating the complex anemia associated with CKD.
Indexed as
Identifiers
21400189What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.